NI201800105A - Anticuerpos, composiciones y antígenos de chaga, métodos y usos de los mismos. - Google Patents

Anticuerpos, composiciones y antígenos de chaga, métodos y usos de los mismos.

Info

Publication number
NI201800105A
NI201800105A NI201800105A NI201800105A NI201800105A NI 201800105 A NI201800105 A NI 201800105A NI 201800105 A NI201800105 A NI 201800105A NI 201800105 A NI201800105 A NI 201800105A NI 201800105 A NI201800105 A NI 201800105A
Authority
NI
Nicaragua
Prior art keywords
antigens
methods
compositions
chaga
antibodies
Prior art date
Application number
NI201800105A
Other languages
English (en)
Inventor
Pleguezuelos Mateo Olga
Romero Caparros-Wanderley Wilson
Alan Stoloff Gregory
Original Assignee
Peptcell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptcell Ltd filed Critical Peptcell Ltd
Publication of NI201800105A publication Critical patent/NI201800105A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente memoria descriptiva describe antígenos de tripanosoma, composiciones inmunogénicas y medicamentos que comprenden los antígenos de tripanosoma, métodos y usos para los antígenos de tripanosoma y composiciones inmunogénicas para el tratamiento contra una enfermedad basada en tripanosoma.
NI201800105A 2016-04-14 2018-10-12 Anticuerpos, composiciones y antígenos de chaga, métodos y usos de los mismos. NI201800105A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662322770P 2016-04-14 2016-04-14

Publications (1)

Publication Number Publication Date
NI201800105A true NI201800105A (es) 2019-02-18

Family

ID=58671580

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201800105A NI201800105A (es) 2016-04-14 2018-10-12 Anticuerpos, composiciones y antígenos de chaga, métodos y usos de los mismos.

Country Status (18)

Country Link
US (2) US10973897B2 (es)
EP (1) EP3442569A1 (es)
JP (1) JP2019513797A (es)
KR (1) KR20190039022A (es)
CN (2) CN116059330A (es)
AU (1) AU2017248680A1 (es)
BR (1) BR112018071108A2 (es)
CA (1) CA3020856A1 (es)
CL (2) CL2018002932A1 (es)
CO (1) CO2018012295A2 (es)
CU (1) CU20180127A7 (es)
EC (1) ECSP18079073A (es)
MX (1) MX2018012504A (es)
NI (1) NI201800105A (es)
PE (1) PE20190104A1 (es)
RU (1) RU2018139865A (es)
SG (1) SG11201808915YA (es)
WO (1) WO2017178660A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020144465A1 (en) * 2019-01-07 2020-07-16 Genome Research Limited Novel trypanosomal vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2731370A1 (de) * 1977-07-12 1979-01-25 Behringwerke Ag Chagas impfstoff und verfahren zu dessen herstellung
ES2169995B1 (es) 2000-04-17 2003-12-01 Leti Lab Composicion a base de la proteina lip2a y su uso en la preparacion de un medicamento para suscitar una respuesta inmune contra un antigeno.
US20040057958A1 (en) 2002-05-17 2004-03-25 Waggoner David W. Immunogenicity-enhancing carriers and compositions thereof and methods of using the same
SA110310855B1 (ar) * 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
US9804158B2 (en) 2013-07-02 2017-10-31 Institut De Recherche Pour Le Développement Peptides and methods for the detection of Leishmaniasis
US9566320B2 (en) 2013-09-24 2017-02-14 The Board Of Regents Of The University Of Texas System Mucin-associated surface protein as vaccine against Chagas disease

Also Published As

Publication number Publication date
EP3442569A1 (en) 2019-02-20
CL2021001441A1 (es) 2021-11-19
WO2017178660A9 (en) 2017-12-07
SG11201808915YA (en) 2018-11-29
PE20190104A1 (es) 2019-01-15
CL2018002932A1 (es) 2019-02-01
CA3020856A1 (en) 2017-10-19
MX2018012504A (es) 2019-08-29
CO2018012295A2 (es) 2019-04-30
RU2018139865A (ru) 2020-05-14
US10973897B2 (en) 2021-04-13
BR112018071108A2 (pt) 2019-02-26
JP2019513797A (ja) 2019-05-30
US20170296637A1 (en) 2017-10-19
US20210220453A1 (en) 2021-07-22
AU2017248680A1 (en) 2018-11-22
CN116059330A (zh) 2023-05-05
KR20190039022A (ko) 2019-04-10
CN109310747A (zh) 2019-02-05
ECSP18079073A (es) 2019-02-28
CU20180127A7 (es) 2019-08-06
WO2017178660A1 (en) 2017-10-19
CN109310747B (zh) 2022-11-22

Similar Documents

Publication Publication Date Title
CL2017002996A1 (es) Compuestos alqueno tetrasustituidos y su uso
AR102657A1 (es) Composición para tratar telas
PE20150646A1 (es) Metodos de tratamiento de una tauopatia
AR104664A1 (es) Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6)
CU20160164A7 (es) Un nanocomplejo micelar
CL2018002692A1 (es) Vacuna bivalente contra el virus de gripe porcina.(divisional solicitud 201701961)
CL2017001661A1 (es) Compuestos biciclicos fusionados para el tratamiento de una enfermedad.
CR20160537A (es) Inhibidor de fosfoinosítido 3-quinasa delta para su uso medico
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR102015017380A2 (pt) dispositivo para a reticulação do tecido do olho, e, composição farmacêutica
CO2019011640A2 (es) Métodos y composiciones para la reducción de la inmunogenicidad
GT201700058A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
CL2016001756A1 (es) Preparación farmacéutica que comprende 0,001-0,003 pv de 6-4-pirazol-1-ilbencilpiridin-3-ilsulfonilaminometilpiridin-2-ilaminoacetato de isopropilo o una sal del mismo uso para el tratamiento o prevención de glaucoma o hipertensión ocular.
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
CO2017007076A2 (es) Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
CL2019001522A1 (es) Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal.
CO2018013828A2 (es) Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
CL2018000513A1 (es) Vacunas de pestivirus para temblores congénitos
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
BR112019000706A2 (pt) agente de estímulo do receptor 1b de 5-hidroxitriptamina para reparo de pele e/ou cabelo
NI201800105A (es) Anticuerpos, composiciones y antígenos de chaga, métodos y usos de los mismos.